AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

Phase 3positiveAtogepantPositive

AI Analysis

Summary

AbbVie announced positive Phase 3 results for atogepant in menstrual migraine, demonstrating statistically significant reductions in migraine days. The data extends AbbVie's migraine portfolio leadership.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Atogepant demonstrated statistically significant reductions in migraine days

Importance:7/10

Sentiment:

0.80

migrainemenstrual migrainePhase 3positive resultsCGRP antagonist

Related Companies

$ABBV

Read the original article

Published by PR Newswire Biotech on September 10, 2026 12:55 PM

Read Original